Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia.
- Author:
Chen CHEN
1
;
Wen WANG
;
Cong-Gao XU
;
Ming HOU
;
Lu-Qun WANG
;
Chuan-Fang LIU
;
Qiang SONG
;
Chun-Yan JI
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adult; Aged; Antineoplastic Agents; blood; therapeutic use; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; blood; drug therapy; Male; Middle Aged; Piperazines; blood; therapeutic use; Pyrimidines; blood; therapeutic use; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2011;32(7):450-453
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze the clinical efficacy of imatinib mesylate (IM) for Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) to couple the trough plasma concentrations (C mins) of IM with clinical responses and adverse events (AEs).
METHODSOne hundred and one CML patients received IM therapy, and Cmins of IM were determined in 30 patients.
RESULTS(1) Cumulative complete hematological response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR) and negative BCR/ABL fusion gene rates were 96.6%, 86.5%, 77.5% and 47.2%, respectively, in CML-CP patients. In accelerated and blastic phases (AP and BC) patients, CHR, MCyR, CCyR and negative BCR-ABL fusion gene rates were 58.3%, 25.0%, 25.0%, 8.3%, respectively. (2) Mean Cmins of IM was significantly higher in the CCyR at 1 year [(1472 +/- 482) microg/L] group than in the non-CCyR at 1 years group [(1067 +/- 373) microg/L] (P < 0.05), and higher in the MMR at 1 year group than in the non-MMR at 1 years group [(1624 +/- 468) microg/L vs (1137 +/- 404) microg/L, P < 0.05].
CONCLUSIONIM significantly improves cytogenetic and molecular response, event-free survival, and overall survival for patients with Ph-positive CML. The Cmins of IM exerts a significant impact on clinical response (CCyR and MMR at 1 year).
